One Case of Thrombopoietin Receptor Ago-nist in the Treatment of Myelodysplastic Syndrome with Thrombocytopenia and Literature Review
-
Published:2022
Issue:12
Volume:12
Page:11001-11006
-
ISSN:2161-8712
-
Container-title:Advances in Clinical Medicine
-
language:
-
Short-container-title:ACM
Publisher
Hans Publishers
Subject
General Engineering
Reference21 articles.
1. Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries
2. Rebulla, P. (2005) A Mini-Review on Platelet Refractoriness. Haematologica, 90, 247-253.
3. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
4. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
5. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial